News & Media

Events
Interim Report January - September 2020

Read more
Events
Interim Report January - June 2020

Read more
Events
Interim Report January - March 2020

Read more
Events
Annual General Meeting 2020

The Annual General Meeting 2020 will be held on 5 May at 2pm CET, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm.

Read more
Events
Kempen Life Sciences Conference

Read more
Events
Wainwright Global Life Sciences Conference

Read more
Events
Redeye Fight Cancer Seminar

Read more
Events
Medivir R&D Day

The meeting will be held at Helio GT30, Grev Turegatan 30, Stockholm, on March 2 at 14:00 to 16:30 CET. To...

Read more
Press release
Invitation to Medivir's R&D Day on March 2, 2020

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday...

Read more
Press release
Medivir and Shijiazhuang Yuanmai Biotechnology sign licensing agreement regarding manufacturing and sales of Xerclear® in China

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the company has signed a licensing agreement for Medivir's Xerclear® for...

Read more
Press release
MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2019

Continued progress with our proprietary and wholly owned candidate drug MIV-818 for liver cancer October – December Significant events during the...

Read more
Press release
Medivir invites to R&D Day on March 2, 2020

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to an R&D Day in Stockholm, Monday...

Read more